Goldman Sachs Maintains Buy Rating on Xylem, Cuts Target to $138
Goldman Sachs cut its price target on Xylem to $138 per share from $160 while maintaining its Buy rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Goldman Sachs Cuts Xylem Price Target to $138 From $160
Goldman Sachs adjusted its price target on Xylem to $138 from $160.